Edmonton, Alberta – Innovotech Inc. (TSXV: IOT) Edmonton, Alberta, January 23, 2026 –
Innovotech Inc. (TSXV:IOT), a leading contract research organization providing proprietary
antimicrobial testing and advanced laboratory services for regulated industries, today
announced that it will participate in the DealFlow Discovery Conference, taking place
January 28-29, 2026.
Craig Milne, CEO of Innovotech Inc. will deliver a company presentation and be available for
one-on-one investor meetings throughout the event. Learn more about Innovotech at
www.innovotech.ca.
Event Details:
● 3rd Annual DealFlow Discovery Conference
● The Borgata Hotel, Casino & Spa
● Atlantic City, NJ
● January 28-29, 2026
Investors interested in scheduling a meeting with the Innovotech Inc management team
should request an investor pass to attend the conference (no cost to attend).
About Innovotech:
Innovotech Inc. is a Canadian boutique contract research organization specializing in
advanced laboratory services and commercializing proprietary technologies. A leader in
biofilm science, the company provides expertise in antimicrobial testing, pharmaceutical
analysis, and industrial laboratory solutions, supported by innovative methodologies and
products including its widely-used MBEC Assay® kit for high-throughput antimicrobial and
antibiotic testing. Innovotech serves clients across multiple sectors, delivering customized
research and testing services designed to meet rigorous regulatory and scientific standards
such as those of the U.S. Food and Drug Administration and Health Canada through its ISOcertified
and GMP-accredited laboratories. Learn more at https://www.innovotech.ca.
Craig Milne, CEO Innovotech Inc.
+1-604-239-1819 craig.milne@innovotech.ca
This document may contain forward-looking statements that are predictive in nature and subject
to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may
differ materially from past results and those expressed or implied by any forward-looking
statements. Factors that could cause or contribute to such risks or uncertainties include, but are
not limited to: the regulatory environment including the difficulty of predicting regulatory
outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number
of customers including government organizations; fluctuations in operating results; government
policies or actions; progress and cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and potential costs associated with its
defense; the Company’s exposure to lawsuits and other matters beyond the control of
management. Should known or unknown risks or uncertainties materialize, or should
management’s assumptions prove inaccurate, actual results could vary materially from those
anticipated. The Company undertakes no obligation to publicly make or update any forwardlooking
statements, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
